Key Takeaways

• Rescheduling cannabis to Schedule III relieves the 280E tax burden for qualifying medical cannabis operators, but it also brings new federal oversight, documentation expectations, and registration requirements that state programs haven’t previously demanded.
• Operators should start strengthening quality systems, supplier controls, inventory management, labeling procedures, and employee training now, not after further federal guidance is issued.
• A cannabis rescheduling consultant can translate evolving requirements into practical systems that support continuous compliance without disrupting operations.

In the cannabis industry, discussions about rescheduling have largely centered on legal and financial implications: Which businesses qualify? What will happen to Section 280E tax deduction exemptions? How will federal and state laws interact? 

But for cannabis operators, those questions are only the beginning. Rescheduling will also require changes to how medical cannabis is produced, documented, stored, transferred, labeled, and tracked. Now subject to a federally regulated framework, businesses will need to demonstrate control over their operations at a level that most state programs have not previously required.

Although some implementation details are still developing, the operational direction is already clear: documentation will matter more, quality systems will face greater scrutiny, and informal processes built on institutional knowledge will become harder to defend.

Operators who start preparing now will have time to make deliberate changes. Those who wait for every federal requirement to be finalized may end up rebuilding critical systems under pressure.

At FP360, we already covered the broader groundwork for building a scalable cannabis operation in our previous post. Here, we will narrow in on what to know about cannabis rescheduling and its impact on operational demands, starting with where things currently stand.

What to Know About Cannabis Rescheduling: The Timeline and What’s Changed

The federal rescheduling process began in 2023, when the Department of Health and Human Services recommended moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. The Department of Justice issued a proposed rule to do so in May 2024.

It wasn’t until December 2025, under an entirely new administration, that an executive order was issued directing the Attorney General to expedite the rescheduling process. In April of the following year, the AG issued a final order placing two categories of cannabis into Schedule III:

• FDA-approved drug products containing cannabis
• Cannabis covered by a state license to manufacture, distribute, or dispense products for medical purposes

For qualifying operators, this order also removes the Section 280E tax burden, allowing them to deduct ordinary business expenses for the first time. (Recreational cannabis stays in Schedule I, and adult-use operators still face the full 280E disallowance.) 

At the same time, a new federal registration system has been launched, as well as a DEA purchase-and-resale mechanism structured to satisfy the US’s obligations under the UN Single Convention on Narcotic Drugs.

Why Cannabis Rescheduling Is an Operational Issue

The rescheduling of medical cannabis has introduced policy shifts that create both opportunity and new pressure for operators.

The immediate financial benefits of Schedule III are significant, particularly the removal of Section 280E for qualifying medical cannabis businesses. Yet the shift also brings state-licensed operators into closer contact with federal controlled-substance requirements.

That means operators will need to show more than general compliance. They will need reliable, documented evidence that their processes work as intended. After all, a written SOP has limited value if each shift follows it differently, and inventory systems are unreliable if physical counts regularly diverge from recorded quantities.

Ultimately, federal registration functions like a controlled-manufacturer standard, and oversight will place greater weight on systems that produce repeatable results and records that can withstand review.

How Cannabis Rescheduling Could Affect Cannabis Operations

Some implementation requirements will continue to take shape through federal rules and guidance. Even so, operators can anticipate where the greatest pressure is likely to fall.

GMP Expectations and Quality Oversight

Schedule III does not automatically turn every state-licensed medical cannabis product into an FDA-approved drug. Operators should be careful about assuming that any specific pharmaceutical standard applies before agencies issue further guidance.

Still, federal recognition of medical cannabis is likely to raise expectations around product consistency, contamination prevention, process control, and quality oversight. 

Operators should be prepared to explain how they:

• Establish product and process specifications
• Control production from batch to batch
• Investigate deviations and out-of-spec results
• Manage corrective and preventive actions
• Approve process, equipment, or material changes
• Verify that controls remain effective

For organizations relying primarily on final-product testing, this will require a broader view of quality. Testing can identify some failures after they occur, but a functioning quality-management system helps prevent them and provides a structured response when something goes wrong.

Documentation and Recordkeeping

Federal controlled-substance requirements place considerable emphasis on traceability. Under the final rule, registered businesses will be expected to maintain records covering the quantities of marijuana manufactured, acquired, distributed, dispensed, or otherwise disposed of.

Many operators already capture portions of this information through state-mandated seed-to-sale systems. The challenge is ensuring consistency across production, inventory, quality, and distribution records.

Operators should review:

• SOP approval and version control
• Batch and production records
• Inventory adjustments and reconciliation
• Cleaning, maintenance, and calibration logs
• Deviation and investigation records
• Product release, hold, and disposition records
• Complaints, returns, and recalls

Documentation created after the fact will be difficult to defend. Records should be completed as the work occurs, reviewed by the appropriate personnel, and readily retrievable.

Labeling and Product Claims

Medical positioning brings increased scrutiny to what a product label says and whether the operation can support it.

Cannabinoid content, dosing information, ingredients, warnings, and product claims should align with approved specifications and testing data. Operators will also need controls in place to keep obsolete labels out of production and medical packaging separate from adult-use.

A documented label-control process should address development, review, approval, issuance, reconciliation, and destruction. Any claim related to a product’s medical use should also receive appropriate regulatory and legal review before shipping. COA-to-label consistency is one of the fastest ways to reduce misbranding risk.

Supplier and Material Controls

A cannabis operation can follow its own procedures and still inherit risk from an unqualified supplier.

Ingredients, cultivation inputs, packaging, testing services, transportation providers, and contract manufacturers can all affect product quality and compliance. As expectations increase, purchasing based on availability or price alone will become harder to defend.

A stronger supplier program includes documented approval criteria, verification of certificates of analysis, defined change-notification requirements, and ongoing performance reviews. Quality agreements can clarify responsibilities when another organization performs work that directly affects the finished product.

Inventory, Storage, and Transfers

Inventory control is already a common point of failure in cannabis operations. Physical counts do not always match Metrc or internal systems. Transfer manifest errors delay receiving, while adjustments may be made without a consistent investigation or approval process.

Federal registration will leave less room for unresolved discrepancies. Operators should be able to trace inventory from receipt or cultivation all the way through production, storage, transfer, dispensing, waste, and destruction. They may also need to strengthen physical security, access controls, segregation practices, and storage arrangements to meet federal requirements.

The United States’ obligations under the Single Convention add another consideration. The federal framework requires the DEA to act as the purchaser of marijuana crops before reselling them within the authorized supply chain. Registered manufacturers will need to store crops in a facility accessible to the DEA until that transaction is complete, which may require substantial changes to how cultivation and manufacturing sites currently operate.

Employee Training and Accountability

New procedures will only improve compliance if employees understand what changed, why it matters, and what they are now responsible for doing.

A training system should go beyond collecting signatures. Employees will need role-specific instruction, documented qualification before working independently, and retraining when procedures change. Competency checks can help confirm whether the training translated into consistent performance.

Responsibilities will also need to be clear. Employees should know who can approve an inventory adjustment, release a product, investigate a deviation, qualify a supplier, or escalate a potential compliance issue.

What Cannabis Operators Should Do Now

Waiting for final guidance may feel like the cautious move. But operationally, it only compresses the time available to find gaps, revise procedures, train employees, and verify that new controls work before those systems are tested.

Operators can begin with a rescheduling readiness assessment. This should examine the business’s current processes against known DEA requirements and the likely demands of increased federal oversight. Findings can then be prioritized according to compliance risk, operational impact, and how long they’ll take to implement.

From there, businesses should focus on a few immediate questions:

• Can every product and material be traced through the operation?
• Do physical inventories consistently match system records?
• Are procedures current, controlled, and followed in practice?
• Can the organization demonstrate employee competency?
• Are suppliers approved and monitored according to documented criteria?
• Are deviations investigated and resolved through a consistent process?

The goal is not to predict every regulation, but to start building an operating system capable of adapting as requirements become clearer.

Build a Rescheduling-Ready System Now With a Cannabis Rescheduling Consultant

Preparing for rescheduling doesn’t require guessing what federal guidance will say. Of course, legal counsel will remain essential for interpreting the federal rule, registration obligations, tax treatment, and the relationship between state and federal law. 

But a cannabis operations consultant addresses the next question: how should those requirements work inside the business? That can mean revising SOPs, building out a quality management system, strengthening inventory controls, qualifying suppliers, or standardizing processes across multiple sites.

At FP360, our cannabis operations consultants begin with a twofold approach:

• FP360’s Rapid Readiness Assessment examines current documentation, traceability, and supplier controls against likely regulatory requirements, with findings prioritized by risk and effort. 
• From there, our Supplier, Vendor & Input Control Program builds the qualification criteria, receiving workflows, and nonconformance processes that hold up under federal-level scrutiny, not just state inspection.

Ultimately, cannabis rescheduling and operations cannot be treated as separate conversations. The businesses best positioned for Schedule III will be those that can demonstrate control before an inspector, registration deadline, or customer requirement forces the issue.

FP360 helps cannabis operators build the documentation, quality systems, training programs, and process controls needed to prepare for changing requirements. 

Schedule a consultation with FP360 to get started.